Post-Market Clinical Follow-up Study with ASPIREX®S to Assess the Safety and Effectiveness in the Treatment of DVT

Inclusion Criteria: 1. Acute thrombotic or thromboembolic occlusion (onset of pain \< 14 days) 2. Age \> 18 years 3. Written informed consent form Exclusion Criteria: 1. Patient not suitable for thrombectomy 2. Fracture area of broken stents 3. Known or suspected allergy to any of the components of the system or to a medicinal product to be administered in connection with the planned procedure 4. Persistent vasospasm 5. Severe coagulatory disorders 6. Patients with thrombophilia 7. Aneurysmatically altered vessel segments on target zone or on passage of catheter 8. Known or suspected infection, especially of the puncture site or the vessel segment being treated 9. Known, unhealed pre-existing mechanical damage to the vessel wall, especially caused by surgical procedures or interventional complications 10. Immature or not fully healed dialysis accesses or bypass grafts 11. Female subjects of childbearing capacity who are not willing to employ contraceptive measures 12. Pregnant or breast feeding subjects 13. Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this study or will not comply with requirements of the study 14. Subjects who are lawfully kept in an institution 15. Subjects who do not have the mental or physical ability to comply with time schedules and further study procedures 16. Current participation in any other clinical study (medicinal, medical device) or within the last 30 days prior to screening